JMP Securities lowered the firm’s price target on Mirum Pharmaceuticals to $66 from $72 and keeps an Outperform rating on the shares. Livmarli continues its strong launch in Alagille syndrome with Q1 sales of $43M topping the firm’s estimate of $42M and Cholbam/Chenodal sales of $26M came in just below the firm’s expectations, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum data published in Lancet shows benefits of Livmarli in PFIC
- Mirum Pharmaceuticals initiated with a Buy at Stifel
- Mirum Pharmaceuticals participates in a conference call with JPMorgan
- Mirum Pharmaceuticals price target lowered to $43 from $44 at Leerink
- Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment